Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 3
- Registration Number
- NCT04801966
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 78
- Registration Number
- NCT04720768
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- Conditions
- Interventions
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1370
- Registration Number
- NCT04711252
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- EnhancedBio USA Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT04669587
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇰🇷CHA Bundang Medical Center, CHA University, Seongnam-si, Korea, Republic of
🇰🇷Kangbuk Samsung Hospital, Seoul, Korea, Republic of
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 559
- Registration Number
- NCT04671615
- Locations
- 🇮🇱
Pfizer Pharmaceuticals Israel Ltd., Herzliya Pituach, Israel
Swedish Ibrance Registries Insights (SIRI)
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1500
- Registration Number
- NCT04654208
- Locations
- 🇸🇪
Pfizer AB, Sollentuna, Sweden
Umbrella Biomarker-Guided Therapy in NPC
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 206
- Registration Number
- NCT04605562
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 186
- Registration Number
- NCT04606446
- Locations
- 🇺🇸
Thomas Jefferson University, Gibbon Building, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Investigational Drug Service, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.